Tomosynthesis is a revolutionary technology that gives radiologists the ability to identify and characterize individual breast structures without the confusion of overlapping tissue. During a tomosynthesis scan, multiple, low-dose images of the breast are acquired at different angles. These images are then used to produce a series of one-millimeter thick slices that can be viewed as a three dimensional reconstruction of the breast.

Instead of viewing all tissue complexities superimposed as they are on a traditional 2D mammogram, the radiologist can now scroll through the layers of the breast in one-millimeter thick slices. Reviewing breast tissue slice by slice removes the confusion of superimposed tissue allowing the radiologist to view a mammogram in a way never before possible.

The Selenia Dimensions system allows you to harness the power of breast tomosynthesis technology to better visualize
masses, distortions and asymmetric densities.²

This latest innovation in breast imaging technology also has a higher cancer detection rate¹ than conventional digital mammography and improves the radiologists' confidence to significantly reduce recall rates.³ Instead of viewing tissue complexities superimposed as they are on a traditional digital mammogram, the radiologist now has the ability to identify and characterize individual breast structures without the confusion of overlapping tissue. During a tomosynthesis scan, multiple low-dose images of the breast are acquired at different angles. These images are then used to produce a series of one-millimeter thick slices that can be viewed as a three-dimensional reconstruction of the breast. This revolutionary new way of looking at breast tissue is changing the paradigm of breast cancer detection.

¹ Skaane P, Gullien R, Eben EB, et. al. Reading time of FFDM and tomosynthesis in a population-based screening program. Radiological Society of North America annual meeting. Chicago, Il, 2011.
² Bernardi D, Ciatto S, Pellegrini M, et. al. Prospective study of breast tomosynthesis as a triage to assessment in screening. Breast Cancer Res Treat. 2012 Jan 22 [Epub ahead of print].
³ FDA PMA submission P080003